1

                    SCHEDULE 14A INFORMATION

   PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
             EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)

Filed by the Registrant [X]

Filed by a Party other than the Registrant [   ]

Check the appropriate box:

                                     
[ ]Preliminary Proxy Statement          [ ] Confidential, for Use of the
[ ]Definitive Proxy Statement           Commission Only (as permitted
[X]Definitive Additional Materials      by Rule 14a-6(e)(2))
[ ]Soliciting Material Pursuant to sec.
240.14a-11(c) or sec. 240.14a-12




                    ICN PHARMACEUTICALS, INC.

        (Name of Registrant as Specified In Its Charter)



  (Name of Person(s) Filing Proxy Statement, if other than the
                           Registrant)

Payment of Filing Fee (Check the appropriate box):

[X]  Fee not required.

[ ]  Fee computed on table below per Exchange Act Rules 14a-
6(i)(4) and 0-11.

  (1) Title of each class of securities to which transaction applies:



  (2) Aggregate number of securities to which transaction applies:



  (3) Per unit price or other underlying value of transaction
      computed pursuant to Exchange Act Rule 0-11 (Set forth the
      amount on which the filing fee is calculated and state how
      it was determined):



  (4) Proposed maximum aggregate value of transaction:



  (5) Total fee paid:



[  ] Fee paid previously with preliminary materials.

[  ] Check box if any part of the fee is offset as provided
     by Exchange Act Rule 0-11(a)(2) and identify the filing for
     which the offsetting fee was paid previously. Identify the
     previous filing by registration statement number, or the Form
     or Schedule and the date of its filing.

  (1) Amount Previously Paid:



  (2) Form, Schedule or Registration Statement No.:



  (3) Filing Party:



  (4) Date Filed:


 2

             SCHERING-PLOUGH AND ICN PHARMACEUTICALS

             ANNOUNCE STRATEGIC LICENSING AGREEMENT


KENILWORTH,  N.J.,  and  COSTA MESA,  Calif.,  Nov.  15,  2000  -
Schering-Plough  Corporation (NYSE: SGP) and ICN Pharmaceuticals,
Inc.  (NYSE: ICN) today announced a long-term strategic agreement
for  the licensing of drugs for the treatment of hepatitis C  and
other indications.
      Under terms of the agreement, Schering-Plough has the right
of  first  and  last  refusal  to  license  two  antiviral  drugs
currently in the ICN research pipeline, levovirin and viramidine,
and  other compounds that ICN may develop in infectious and other
diseases,  as  well  as  the exclusive option  for  an  exclusive
worldwide  license  for  up to three  hepatitis  C  drugs  to  be
developed by ICN.
      "ICN  and  Schering-Plough have an excellent  and  mutually
rewarding business relationship that will now continue well  into
the future," said Milan Panic, chairman and CEO of ICN.  "We look
forward to continuing our already successful relationship in  the
battle against hepatitis C and other diseases," Panic said.
      "We  are  pleased  to enter into this new agreement,  which
continues  our successful relationship with ICN and provides  the
opportunity  to  expand and complement Schering-Plough's  ongoing
research  efforts  in  hepatitis and other infectious  diseases,"
said Thomas C. Lauda, executive vice president, global marketing,
Schering-Plough Pharmaceuticals.
      Royalty  rates and other financial terms of  the  agreement
were not disclosed.
     It is estimated that about 2 percent of the world population
is  currently infected with the hepatitis C virus.  This includes
some  4  million Americans, according to the Centers for  Disease
Control and Prevention (CDC), and as many as 5 million Europeans,
according  to  a study conducted by the World Health Organization
(WHO).  Chronic hepatitis C is the leading cause of chronic liver
disease  and  the  most  common  reason  for  liver  transplants,
according to WHO.
      The  new  agreement also resolves claims by Schering-Plough
related to the hiring of former Schering-Plough scientists by ICN
and the existing licensing agreement between the two companies.
      ICN  is an innovative, research-based global pharmaceutical
company that manufactures, markets and distributes a broad  range
of  prescription and non-prescription pharmaceuticals  under  the
ICN  brand  name.   Its therapeutic focus is on  anti-infectives,
including   antivirals,  dermatology  and  oncology.   Additional
information  is  also  available on the  company's  Web  site  at
http://www.icnpharm.com
        Schering-Plough   Pharmaceuticals   is   the    worldwide
pharmaceutical  research  and marketing  arm  of  Schering-Plough
Corporation,  a research-based company engaged in the  discovery,
development,   manufacturing  and  marketing  of   pharmaceutical
products worldwide.